Isolation, characterization and antimicrobial evaluation of a novel compound N-octacosan 7β-ol, from Fumaria parviflora Lam

Mohammad Jameel1, Mohammad Islamuddin2, Abuzer Ali1, Farhat Afrin2 and Mohammed Ali1*

Abstract

Background: Fumaria parviflora Lam. (Fumaraceae) is widely used in traditional as well as folkloric system of medicine from ancient. It is commonly known as ‘Pitpapa’ or ‘Shahtrah’ in Indian traditional system of medicine and used for treating numerous ailments like diarrhea, fever, influenza, blood purifier and other complications. The object of the present study was to evaluate the Antileishmanial, antibacterial, antifungal and cytotoxic potential of isolated compound.

Methods: Methanolic extract of whole plant of Fumaria parviflora was dried under reduced pressure to obtain a dark brown residue which was adsorbed on silica gel column grade (60–120 mesh) to obtain a slurry and chromatographed over silica gel loaded column in petroleum ether – chloroform (3:1, 1:1 and 1:3 v/v). The in vitro antileishmanial evaluation of isolated compound against Leishmania donovani promastigotes was investigated by growth kinetics assay, reversibility assay, analysis of cellular morphology, adverse toxicity and determination of 50% growth inhibitory concentration (GI50). Disc diffusion and broth micro dilution methods were used to study the antibacterial (Gram + Staphylococcus epidermidis and Bacillus subtilis; Gram - Escherichia coli and Salmonella typhimurium) and antifungal (Candida albicans and Aspergillus niger) potential in vitro.

Results: Structure elucidation by spectral data analysis revealed a novel compound, n-octacosan-7β-ol (OC), yield (0.471%), having significant antimicrobial activity against Leishmania donovani promastigotes, Staphylococcus epidermidis, Escherichia coli, Candida albicans and Aspergillus niger in vitro with GI50 = 5.35, MIC 250, MIC 250 and MFC 500 and MIC 250 μg ml⁻¹ respectively. The isolated compound did not show adverse effect against mammalian macrophages.

Conclusions: The available evidence of compound suggested that it may be used as antimicrobial agent in future and may provide new platform for drug discovery programmes for leishmaniasis.

Keywords: Fumaria parviflora, Homaira, Shahtrah, Leishmanial potential, Novel, Isolation

Background

The traditional medicine has been a vibrant, innovation-driven highly successful component of global industry and confluence of spectacular advances in chemistry, molecular biology, genomics and the cognate fields of spectroscopy, chromatography and crystallography led to the new findings and development of numerous novel curative agents for the treatment of a wide spectrum of ailments [1]. They have formed the basis of sophisticated traditional medicine systems among which Ayurvedic, Unani and Chinese systems have given ascent to crucial unmatched lead molecules still in use today [2]. The number of higher medicinal plant species on this planet is estimated at 250,000 [3] but of these only about 6% have been screened for biological activity, 15% have been evaluated phytochemically [4] and only about 0.75% herbal drugs have been studied in clinical trials [5]. So the search for new molecules nowadays has taken a faintly different route where the science of ethanomedicine is being used as a
guide to lead the chemist towards different sources and classes of molecules [2].

*Fumaria parviflora* Lam. is widely used in traditional and as well as folkloric system of medicine named as “fumitory, earth smoke, beggary, fumus, vapor and fumitory or wax dolls” in English [6]. It is locally known as ‘Pitpapra’ or ‘Shahtrah’ in India [7], “Homaira” in Saudi Arabia [8]. Phytochemical investigation of this medicinal plant revealed the presence of several alkaloids [9,10], and shown to possess pharmacological activities like antipyretic [11], hepatoprotective [12], hypoglycemic [13], antidiarrheal, antispasmodic, bronchodilator [14], anthelmintic [15], antieczema [16] and nematocidal activities [17].

Visceral leishmaniasis is an infectious disease caused by protozoan parasite, *leishmania donovani* which is considered as a major public health trouble in developing countries [18]. Primary health care systems are not always significant to use the herbal medicines in common practice because very few studies were carried out to investigate the potential use of these medicinal plants in treatment of parasitic diseases [19]. The chemotherapeutic interventions against visceral leishmaniasis (VL) are limited and facing severe concerns of toxicity, high cost, and drug resistance [20]. In view of that concern an integrated approach towards the discovery and development of novel chemical entity with ethanopharmacological implications for promotion and development of leads for *leishmaniaisis* as well as traditional medicine, remains a significant hope in the current, target-rich scenario which may offer unprecedented diversity in structures and bioactivity. So isolation, characterization and antimicrobial evaluation has been aimed for novel bioactive compound by chromatographic techniques, and bacterial strain (Gram + *Staphylococcus epidermidis* and *Bacillus subtilis*; Gram - *Escherichia coli* and *Salmonella typhimurium*), fungal strain (*Candida albicans* and *Aspergillus niger*) and *Leishmania donovani* promastigotes.

**Methods**

**Materials**

M199 medium, RPMI 1640 medium were obtained from Sigma-Aldrich, fetal bovine serum (FBS) from Gibco-BRL, DMSO from SRL and methanol from Merck. All other chemicals were from Sigma-Aldrich unless otherwise stated. Melting point was determined on a Perfit apparatus without correction. The IR spectrum was measured in KBr pellet on a Bio-Red FT-IR spectrometer. UV spectrum was obtained in methanol with a Lambda Bio 20 spectrometer, 1H (400 MHz), 13C (100 MHz), NMR spectra were recorded on Bruker spectrospin spectrometer. CDCl3 (sigma-Aldrich) were used as solvent and TMS as an internal standard. ESI- MS analysis was performed on a Synapt Mass spectrometer (Waters) equipped with a direct inlet probe system. Column chromatography separations were carried out on column grade silica gel (Merck, 60–120 mesh). Precoated silica gel plates (Merck, Silica gel 60 F254) were used for analytical thin layer chromatography (TLC) visualized by exposure to iodine and UV radiations. Microbial strains used for the antimicrobial evaluation, a panel which included laboratory control bacterial strains (Gram + *Staphylococcus epidermidis* and *Bacillus subtilis*; Gram - *Escherichia coli* and *Salmonella typhimurium*) fungal strains (*Candida albicans* and *Aspergillus niger*), and *Leishmania donovani* promastigote.

![Proton NMR spectrum of OC, at 400 MHz in CDCl3.](image_url)
Streptomycin, amphotericin B and DMSO analytical grade used for positive and negative control respectively.

Methods

Plant material

The Fumaria parviflora Lam. (whole plant) was collected from the herbal garden of Jamia Hamdard, New Delhi and identified by Prof. Javed Ahmad, Incharge herbal garden. A specimen voucher of the drug was deposited to the Phytochemistry Research Lab (PRL) with a reference number PRL-JH/2011/05.

Parasite culture

L. donovani strain AG83 was a kind gift from Dr. Nahid Ali (IIICB, Kolkata, India) and was maintained in vivo in BALB/c mice. Promastigotes were maintained in medium M199 supplemented with 100 U ml⁻¹ sodium penicillin G and 100 μg ml⁻¹ streptomycin sulfate (incomplete medium) and 10% heat-inactivated FBS at 22°C, and subcultured every 72 h in the same medium at a mean density of 2 × 10⁶ cells/ml [21].

Preparation of crude extract and isolation

The dried F. parviflora Lam. whole plant (1.25 kg) was coarsely powdered and extracted with methanol for 72 h using a Soxhlet extractor. The extract was dried under reduced pressure to obtain a dark brown residue (190 g). The residue (100 g) was dissolved in minimum amount of methanol and adsorbed on silica gel column grade (60–120 mesh) to obtain slurry. The slurry was dried in air and chromatographed over silica gel column loaded in petroleum ether. The column was eluted with petroleum ether and petroleum ether–chloroform (3:1, 1:1, 1:3 v/v) mixtures.

General procedure for antimicrobial evaluation

Antimicrobial activity

Agar disc diffusion method and broth microdilution method were employed for the determination of antibacterial and antifungal activities. The minimum inhibitory concentration (MIC), minimum bactericidal (MBC), minimum fungicidal concentration (MFC) [22] and the inhibition zone of the OC against the test microorganisms were determined by the broth microdilution method. The MIC, MBC, MFC and the inhibition zone of the n-octacosan-7β-ol (OC) were also determined in parallel experiments in order to control the sensitivity of the test microorganisms.

A suspension of the bacterial strain (Gram+ Staphylococcus epidermidis and Bacillus subtilis; Gram - Escherichia coli and Salmonella typhimurium), fungal strain (Candida albicans and Aspergillus niger) (0.1 ml of 10⁵ CFU ml⁻¹) was spread on the solid media plates. Nutrient agar and Czapek Dox Agar sterilized in a flask and cooled to 45–50°C were distributed to sterilized Petri dishes with a diameter of 9 cm (15 ml). The filter paper discs (6 mm in diameter) were individually impregnated with 50 μl (1000 μg ml⁻¹) of the OC and then placed onto the agar plates which had previously been inoculated with the tested microorganisms. The plates were inoculated with bacterial strains incubated at 37°C for 24 h and at 28°C for 48 h for
the fungal strains. The diameters were measured in millimeters. Streptomycin (10 μg/disk) was used as a positive control for bacteria, amphotericin B (5 μg/disk) as a positive control for fungi, and DMSO was used as the negative control. All assays were done in duplicate. A broth microdilution method was used to determine the MIC, MBC and MFC according to the National Committee for Clinical Laboratory Standards [23]. All tests were performed in Nutrient broth and Czapek-Dox broth supplemented with ethanol at final concentration of 0.5% (v/v) for all microorganisms. Two folds serial dilutions of the OC were prepared in a 96-well microtiter plate ranged from 1000 μgm l-1 to 1.038 μgm l-1. Overnight broth cultures of each strain were prepared and the final concentration in each well was adjusted to 105 CFU ml-1 for bacterial strains and fungal strains. 96-well microtiter plate injected with fungal strain was incubated at 28°C for 48 h, and the bacteria were incubated at 37°C for 24 h. The MIC is defined as the lowest concentration of the OC at which the microorganism does not demonstrate visible growth. To determine MBC and MFC, 10 μl broth was taken from each well and inoculated in Nutrient for 24 h at 37°C for bacteria or in Czapek Dox agar for 48 h at 28°C for the fungi. The MBC is defined as the lowest concentration of the OC at which inoculated bacteria were completely killed. The MFC is defined as the lowest concentration of the OC at which inoculated fungi were completely killed. All determinations were performed in duplicate and two growth controls consisting of Nutrient Agar and Czapek Dox agar medium were included. The streptomycin and amphotericin B served as a positive control.

### Growth kinetics assay
Promastigotes of *L. donovani* strain MHOM/IN/83/AG83 (2 × 10⁶ cells ml⁻¹) were incubated in the presence of OC in M199 containing 10% FBS (complete medium) at a concentration of 100 μg ml⁻¹. Pentamidine (100 μg ml⁻¹) served as the reference antileishmanial drug, while 0.2% DMSO, which represented the highest concentration in the test compound, was used as a solvent control. Parasites in medium alone were taken as control. Viable parasites were enumerated for 7 days using a phase-contrast microscope under a 40X objective [24].

### Growth reversibility assay
To confirm the leishmanicidal effect of OC, treated and untreated parasites after 7 days of incubation were washed twice with incomplete medium and finally resuspended in complete medium and cultured at 22°C for a further 96 h.

### Table 1 Antibacterial and antifungal activities of OC as inhibition zones (mm)

| Treatment                  | OC (mm) | Control (mm) | Streptomycin (mm) | Amphotericin B (mm) |
|----------------------------|---------|--------------|-------------------|---------------------|
| Staphylococcus epidermidis (Gram +) | 14      | 6            | 24                | -                   |
| Bacillus subtilis (Gram +)     | 6       | 6            | 17                | -                   |
| Escherichia coli (Gram -)      | 11      | 6            | 16.5              | -                   |
| Salmonella typhimurium (Gram -) | 6       | 6            | 18                | -                   |
| Candida albicans              | 12      | 6            | -                 | 17                  |
| Aspergillus niger             | 11.5    | 6            | -                 | 15.5                |

(−) no activity, OC (n-octacosan-7β-ol), Streptomycin (Positive control for bacterial strain) and Amphotericin B (Positive control for fungal strain).

### Table 2 Minimum inhibitory concentrations (MIC), minimum bactericidal concentrations (MBC) and minimum fungicidal concentrations (MFC) of OC

| Treatment                  | OC (µg/ml) | Streptomycin (µg/ml) | Amphotericin B (µg/ml) |
|----------------------------|------------|----------------------|------------------------|
| Staphylococcus epidermidis | 250        | 6.25                 | -                      |
| Escherichia coli           | 250        | 50                   | -                      |
| Candida albicans           | 500        | 50                   | -                      |
| Aspergillus niger          | 500        | -                    | 2.07                   |

(−) no activity, OC (n-octacosan-7β-ol), Streptomycin (Positive control for bacterial strain) and Amphotericin B (Positive control for fungal strain).
The viability of the parasites was ascertained microscopically [24].

**Analysis of cellular morphology**

Morphology of the promastigotes was evaluated after 96 h of treatment with the test OC, pentamidine and or 0.2% DMSO and photomicrographs were taken at 400x magnification under phase-contrast microscope [25].

**Determination of GI50**

To determine the GI50 (concentration of compound that inhibited growth of parasites by 50%), promastigotes at a density of $2 \times 10^6$ cells ml$^{-1}$ were incubated in triplicate with or without OC at serial three fold dilutions starting from 100 μg ml$^{-1}$ for 96 h. Pentamidine served as the reference drug [26].

**Cytotoxicity to mammalian cells**

Macrophages were collected by peritoneal lavage from starch-stimulated mice. Peritoneal cells were collected in RPMI 1640 medium (incomplete), pelleted by centrifugation at 800 x g for 10 min at 4°C, washed twice and finally resuspended in complete medium. Macrophages at a cell density of $1 \times 10^6$ cells ml$^{-1}$ were incubated with OC at varying concentrations for 48 h in a CO$_2$ incubator (5% CO$_2$, 37°C). Pentamidine served as reference drug and 0.2% DMSO as solvent control. Macrophages without any treatment were taken as control. Cells were observed under phase-contrast microscope and viability was ascertained after trypan blue staining [26].

**Results**

**Structural elucidation of isolated compound**

Elution of the column with ratio of petroleum ether-chloroform afforded star-shaped colorless of OC, recrystallized from chloroform-methanol (1:1), 3.1 g (0.471% yield); R$_f$ 0.54 ± 0.02 (petroleum ether-chloroform, 1:1 v/v), m.p. 74–75°C; UV λ max (MeOH); 209 nm (log ε 3.6); IR λ max (KBr); 3318, 2954, 2848, 1465, 1378, 1236, 1134, 857, 721 cm$^{-1}$; $^1$H NMR (CDCl$_3$); δ 3.67 (1H, brm, w$_{1/2}$ = 14.1 Hz, H-7α), 2.36 (2H, m H$_2$-6), 2.14 (2H m, H$_2$-8), 1.70 (4H, m, 2xCH$_2$), 1.51 (8H, m, 4x CH$_2$), 1.34 (34H, 17x CH$_2$), 0.98 (3H, t, J = 6.0, Me-1), 0.95 (3H, t, J = 6.8, Me-28); $^{13}$C NMR (CDCl$_3$); δ 72.06 (C-7), 37.50 (CH$_2$), 31.95 (CH$_2$), 31.91 (CH$_2$), 29.73 (6x CH$_3$), 29.67 (7x CH$_2$), 29.61 (5x CH$_2$), 29.40 (CH$_3$), 29.36 (CH$_2$), 25.68 (CH$_2$), 22.72 (CH$_2$), 14.16 (Me-1, Me-28). +ve ESI-MS m/z (rel. int.); 411 [M+1]$^+$ corresponding to a molecular formula of an
octacosyl alcohol, C_{28}H_{59}O. The ion peak arising at m/z 325 \([\text{CH}_3(\text{CH}_2)_{20}\text{CHOH}]^+\) indicated the presence of the hydroxyl group at C-7. The \(^1\)H NMR spectrum of OC (Figure 1) showed a one proton broad multiplet at \(\delta 3.67\) with half width of 14.1 Hz was ascribed to \(\alpha\)-oriented \(\text{H-7}\) carbinol proton. The methylene protons resonated between \(\delta 2.36-1.34\). Two three-proton triplets at \(\delta 0.98\) (\(J= 6.0\)) and 0.95 (\(J= 6.8\)) were accounted to C-1 and C-28 primary methyl proton respectively. The \(^{13}\)C NMR spectrum of OC (Figure 2) displayed signals for carbinol carbon at \(\delta 72.06\) (C-7), methylene carbons between 37.50-22.72 and methyl carbon at \(\delta 14.16\) (C-1, C-28). The \(^1\)H-\(^1\)H COSY spectrum of OC (Figure 3) exhibited correlations of Me-1 with H\(_2\)-2 and H\(_2\)-3; H-7 with H\(_2\)-6, H\(_2\)-5, H\(_2\)-8 and H\(_2\)-9; and Me-28 with H\(_2\)-27 and H\(_2\)-26. The absence of any proton singlet beyond \(\delta 3.67\) and carbon signal after \(\delta 72.06\) in the down field region suggested saturated nature of the molecule. On the basis of foregoing account the structure of OC was elucidated as n-octacosan-7\(\beta\)-ol (Figure 4).

**Antibacterial and antifungal study**

The values (mm) of inhibitory zones for the bacterial and fungal strain are studied by disc diffusion method and results are mentioned in Table 1. The diameter of the zone of inhibition is expressed in millimeter including the disc (6 mm). The OC presented antimicrobial activity against the *Staphylococcus epidermidis*, *Escherichia coli*, *Candida albicans* and *Aspergillus niger*, showing the biggest inhibition zones. The results of the Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) are presented and mentioned in Table 2. The analyzed compound OC expressed strong antibacterial and antifungal potential.

**In vitro antileishmanial activity by growth kinetics assay**

The isolated OC was assayed for its cytotoxicity against *L. donovani* promastigotes which exhibited time-dependent killing of promastigotes at a concentration of 100 \(\mu\)g ml\(^{-1}\). No viable parasites were observed after 2 and 3 days of incubation with pentamidine and OC, respectively (Figure 5). Untreated parasites proliferated at a normal rate.

**Alteration of cellular morphology**

Visual inspection by phase-contrast microscopy revealed the onset of cell shrinkage and cytoplasmic condensation upon treatment of promastigotes with OC (100 \(\mu\)g ml\(^{-1}\)) (Figure 6), marked by complete circularization of almost all the cells at 96 h post-treatment. Similar morphological changes were observed in pentamidine-treated parasites. Microscopic study indicated that the effect was leishmanicidal rather than leishmanistatic.

**Growth reversibility assay**

To confirm the lethal effect of OC for promastigotes, treated and untreated parasites (from the growth kinetics study) were washed and resuspended in fresh medium and their viability was ascertained microscopically after 96 h of incubation. No viable parasites were detected after incubation with OC, as it was also observed with pentamidine, confirming their leishmanicidal effect (Figure 7).
Evaluation of the GI50 against promastigotes

The viability of promastigotes after treatment with OC was evaluated using a modified GI50 assay and its demonstrated dose-dependent inhibition of parasite growth with GI50 achieved at 5.35 μgm l⁻¹. The established antileishmanial drug pentamidine, used as a positive control, showed a similar trend in dose-dependent parasite killing, with a GI50 of 2.9 μg ml⁻¹ (Figure 8). Exposure to DMSO (0.2%), representing the highest concentration of diluent, showed no loss of parasite viability.

Cytotoxicity on mammalian macrophages

Peritoneal macrophages were isolated from mice to check for any adverse side effects of the bioactive OC, using pentamidine as the reference drug. The cytotoxicity assay revealed that there was no adverse toxicity of OC, even at 200 μg ml⁻¹, on mammalian macrophages (Figure 9).

Discussion

Natural products compounds have been the mainstay of several drug discoveries since the early days of the antibiotic era due to challenge posed by antibiotic resistance. Discovery and development of a new leads of antimicrobial drugs as well as many others could be better explained by reverse pharmacology which is an evolutionary process, based on traditional knowledge which facilitates not only to search experimental database for many novel leads but also minimize time, money and toxicity since several years. VL is considered as an opportunistic infection among immunocompromised patients and mainly treated with toxic pentavalent antimonials, second line drugs such as amphotericin B and pentamidine. Currently there is no vaccine and resistance to antimonial
chemotherapy, coupled with its high cost, toxicity and parental route of administration, is a matter of great concern in endemic regions of developing countries [27]. Due to severe adverse and toxic profile of synthetic molecules, it is essential requirement for routine screening for safer bioactive compounds from medicinal, aromatic and food plants. Hence there could be no doubt to search for novel antimicrobial agent having antileishmanial potency is one of the core challenges in the current drug discovery programme and this worldwide problem. Previously reports exhibited as anthelmintic [15] and nematocidal activity from extract of _F. parviflora_ [17] but still no report of such activity by novel isolated molecule as n-octacosan-7β-ol, OC (0.471% yield) may be a new hope for this widespread problem.

**Conclusion**

In this study we found that OC isolated from _F. parviflora_ having bactericidal, fungicidal and leishmanicidal activity (Figure 10). In view of the ongoing challenge to introduce new antimicrobial agent as well as potent leishmanicidal drugs which showed dose dependent as well as time dependent parasite killing rate, indicated the potency of OC with respect to pentamidine are anticipated to provide a fresh platform. This study showed that OC have potent antibacterial and antifungal activities against _S. epidermidis_, _E. coli_, _C. albicans_ and _A. niger_. These results indicate that the compound might be a practical application in the prevention and protection against bacterial (gram + and gram-), fungal and leishmanial infections in animals and humans.

**Abbreviations**

OC: n-octacosan-7β-ol; VL: Visceral leishmaniasis.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MJ carried out procurement, extraction, study, drafting and isolation work along with AA, MA has made study design, supervise, interpretation of the isolated compound and revision of the manuscript. MI and FA have contributed in Antileishmanial study. All authors read and approved the final manuscript.

**Acknowledgement**

The authors are very thank full to Central Council for Research in Unani Medicine, New Delhi, India and Jamia Hamdard University, New Delhi, India, for providing research and instrumental facility such as NMR, FT-IR and LC-MS.

**Author details**

1. Phytochemistry research Lab., Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India. 2. Parasite Immunology Lab., Department of Biotechnology, Faculty of Science, Jamia Hamdard, New Delhi 110062, India.

Received: 13 November 2013 Accepted: 5 March 2014 Published: 12 March 2014

**References**

1. Frantz S: Approvals: the demise of the blockbuster. Nat Rev Drug Discov 2004, 4:93–94.
2. Fakim AG: Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Med 2006, 27:1–93.
3. Ayensu ES, De- Filipps RN: Endangered and Threatened Plants of the United States. Washington, DC: Smithsonian Institution; 1978.
4. Verpoorte R: Pharmacognosy in the new millennium: lead finding and biotechnology. J Pharm Pharmacol 2000, 52:253–262.
5. Mohammed A: Present status of herbal medicines in India. Journal of herbal medicine and toxicology 2003, 3:2(1):7–.
6. Orhan I, Sener B, Muzhanaf SG: Antioxidant and hepatoprotective activity appraisal of four selected _Fumaria_ species and their total phenol and flavonoid quantities. Exp Toxicol Pathol 2010, 64(1):205–209.
7. Chopra RN, Nayar SL, Chopra IA: _Glossary of Indian Medicinal Plants_. New Delhi National Institute of Science Communication and Information Resources (CSIR); 2002:122.
8. Mossa JS, Al-Yahya MA, Al- Meshal IA: Medicinal Plants of Saudi Arabia, 1st ed. Riyadh. ISBN 9960-36- 476– 476-
9. Popova ME, Simeonov V, Delejs L, Smyrl B, Reininger V: Alkaloids from _Fumaria parviflora_ and _Fumaria Kralikii_. Planta Med 1982, 45:120–122.
10. Rahman AU, Bhati MK, Choudhary MI, Sener B: Chemical constituents of _Fumaria indica_. Fitoterapia 1992, 63:29–135.
11. Khattak SG, Glani SN, Ikram M: Antipyretic studies on some indigenous Pakistani medicinal plants. J Ethnopharmacol 1985, 14:45–51.
12. Glani AH, Iqbal ZH, Akhtar MG: Selective protective effect of the extract from _Fumaria parviflora_ on paracetamol-induced hepatotoxicity. Gen Pharmacol 1996, 27:797–983.
13. Akhtar MS, Khan QM, Khalig T: Effect of _Euphorbia prostrata_ and _Fumaria indica_ in normoglycemic and alloxan-treated hyperglycemic rabbits. Planta Med 1984, 50:140–142.
14. Rehman N, Bashir S, Al-Rehaily AJ, Gilani AH: Mechanisms underlying the antidiabetic, antispasmodic and bronchodilator activities of _Fumaria parviflora_ and involvement of tissue and species specificity. J Ethnopharmacol 2012, 144:128–137.
15. Hordgen P, Hertzberg H, Hellmann J, Langhans W, Maurer V: The anthelmintic efficacy of five plant products against gastrointestinal trichostongylids in artificially infected lambs. Veterinary Parasitology 2003, 117:51–60.
16. Jowkar F, Jamshidzadeh A, Yazdi AM, Pasalar M: The effects of _Fumaria Parviflora_ L extract on chronic hand eczema: a randomized double-blind placebo controlled clinical trial. Iranian Red Crescent Medical Journal 2011, 13(11):824–828.
17. Naz I, Rius JEP, Safaullah BLock V, Khan MR, Ali S, Ali S: vitro and in planta nematocidal activity of _Fumaria parviflora_ (Fumariciaceae) against the southern root-knot nematode _Meloidogyne incognita_. Plant Pathol 2012. doi:10.1111/j.1365-3059.2012.02682.x.
18. Anonymous: Control of the leishmaniasis. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1990, 793:1–158.
19. Khalid SA, Farouk A, Geary TG, Jensen JB: Potential antimalarial candidates from _African_ plants: in an vitro approach using _Plasmodium falciparum_. J Ethnopharmacol 1985, 18:201–209.
20. Singh N, Kumar A, Gupta P, Chand K, Samant M, Maurya R, Dube A: Evaluation of antileishmanial potential of _Tinospora sinensis_ against experimental visceral leishmaniasis. Parasitol Res 2008, 102(3):561–565.
21. Afrin F, Rajesh R, Anam K, Copinath M, Pal S, Ali N: Characterization of _Leishmania donovani_ antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 2002, 70:6697–6706.
22. Hernandez T, Canales M, Avila JG, Garcia AM, Martinez A, Caballero J, Romo de Vivar A, Lira R: Composition and antibacterial activity of essential oil of _Lantana achyranthifolia_ Desf. (Verbenaceae). J Ethnopharmacol 2005, 96:551–554.
23. Jones MR: Reinterpretation of Susceptibility Data Using Current NCCLS Breakpoint Criteria, _Antimicrob Agents Chemother_ 2003, 47(2):830.
24. Afrin F, Dey T, Arom K, Ali N: Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J Parasitol 2001, 87:188–193.
25. Dutta A, Ghoshal A, Mandel D, Mondal NB, Banerjee S, Sahu NP, Mandal C: Racemoside A, an anti-leishmanial, water soluble, natural steroidal saponin, induces programmed cell death in _Leishmania donovani_. J Med Microbiol 2007, 56:116–1204.
26. Islamuddin M, Farooque A, Dwarakanath BS, Sahal B, Afrin F: Extracts of Artemisia annua leaves and seeds mediate programmed cell death in Leishmania donovani. J Med Microbiol 2012, 61:1709–1718.

27. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW: Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000, 31:1104–1107.

doi:10.1186/1472-6882-14-98

Cite this article as: Jameel et al: Isolation, characterization and antimicrobial evaluation of a novel compound N-octacosan 7β ol, from Fumaria parviflora Lam. BMC Complementary and Alternative Medicine 2014, 14:98.